 The purpose of this trial was to find an optimal dose for a new trial drug - degarelix FE200486 - in the treatment of prostate cancer. Furthermore the safety of the drug was studied. Patients participating were treated with FE200486 on one occasion. Thereafter they came in for visits following a specific schedule until blood samples showed that there was no further effect. 